$3.50
-0.08 (-2.23%)
Open$3.60
Previous Close$3.58
Day High$3.60
Day Low$3.49
52W High$5.55
52W Low$2.83
Volume—
Avg Volume518.9K
Market Cap214.50M
P/E Ratio—
EPS$-1.98
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+1,226.9% upside
Current
$3.50
$3.50
Target
$46.44
$46.44
$29.94
$46.44 avg
$64.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 40.10M | 40.27M | 42.57M |
| Net Income | -118,893,512 | -107,466,265 | -129,666 |
| Profit Margin | -296.5% | -281.7% | -0.3% |
| EBITDA | -126,902,125 | -121,077,652 | -158,434 |
| Free Cash Flow | — | — | -114,389 |
| Rev Growth | -0.4% | -0.4% | +21.1% |
| Debt/Equity | — | — | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |